Ga68-DOTATOC PET/CT clinical impact in patients with neuroendocrine tumors (preliminary results)

#3258

Introduction: Ga68-DOTATOC PET/CT enables the detection of cells with overexpression of somatostatin receptors, especially subtypes 2 and 5. This is the basis for its use in the study of neuroendocrine tumors (NETs). Detection of a higher number of lesions is not necessarily followed by a modification of therapeutic approach. From our point of view this is the main success of this technique the impact in the management of these patients.

Aim(s): The aim of this study was to assess the impact of Ga68-DOTATOC PET/CT on the clinical management of patients with suspected NET.

Materials and methods: A prospective observational study was conducted in 12 patients who underwent a Ga68-DOTATOC PET/CT. They were suspected of neuroendocrine tumor lesions, either on initial diagnosis or as a possible recurrence/progression of already known tumors. The results of prior imaging studies had been negative or inconclusive. PET results were correlated with histological findings and clinical decisions.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Suarez-Piñera M, Domenech B, Rivera E, Visa L, Iglesias M,

Keywords: Ga68-DOTATOC PET/CT, clinical management,